盐酸埃克替尼治疗晚期非小细胞肺癌后长期生存病例分享  

Long term survival of a patient with advanced non-small cell lung cancer under icotinib therapy

作　　者：张力[1] 关秋红[2] 夏莹[1] 赵艳伟[1] 肖毅[1] 

机构地区：[1]中国医学科学院北京协和医院,北京100005 [2]北京中医药大学东直门医院,北京100700

出　　处：《中国新药杂志》2013年第12期1435-1437,共3页Chinese Journal of New Drugs

摘　　要：本文分享1例以埃克替尼为主要治疗方法的IV期脑转移肺腺癌患者,目前无疾病进展时间46个月,获得长期生存,未发生腹泻和皮疹等不良反应,客观疗效为部分缓解(PR),表明盐酸埃克替尼治疗晚期非小细胞肺癌(NSCLC)的长期存活情况与吉非替尼和厄罗替尼相似,具有较好的有效性、安全性和耐受性。与吉非替尼和厄罗替尼相比,其不良反应较少。Icotinib was administrated as the major treatment to a IV-level pulmonary adenocarcinoma pa- tient with brain metastasis. So far progress free survival （PFS） has reached 46 months, and adverse events such as rash and diarrhea have not been observed as well. Objective effectiveness is determined as partial response （PR）. The case in question suggests that icotinib therapy is likely to achieve a long term survival that resembles to those of gefitnib and erlotinib therapies in advanced NSCLC patients. Meanwhile icotinib is more effective and better-tolera- ted thus superior to gefitinib and erlotinib in efficacy and adverse reactions.

关 键 词：表皮生长因子受体 酪氨酸激酶抑制剂 非小细胞肺癌 盐酸埃克替尼 长期生存 

分 类 号：R979.1[医药卫生—药品]